Compare WVE & MLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WVE | MLCO |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | Singapore | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | 2015 | 2006 |
| Metric | WVE | MLCO |
|---|---|---|
| Price | $13.40 | $6.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 6 |
| Target Price | ★ $29.94 | $9.42 |
| AVG Volume (30 Days) | ★ 4.0M | 2.1M |
| Earning Date | 03-03-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | $109,230,000.00 | ★ $5,061,044,000.00 |
| Revenue This Year | N/A | $13.56 |
| Revenue Next Year | $16.20 | $2.49 |
| P/E Ratio | ★ N/A | $24.75 |
| Revenue Growth | ★ 103.75 | 11.46 |
| 52 Week Low | $5.28 | $4.55 |
| 52 Week High | $21.73 | $10.15 |
| Indicator | WVE | MLCO |
|---|---|---|
| Relative Strength Index (RSI) | 43.21 | 30.46 |
| Support Level | $13.22 | $5.90 |
| Resistance Level | $14.51 | $6.40 |
| Average True Range (ATR) | 1.33 | 0.26 |
| MACD | -0.38 | -0.04 |
| Stochastic Oscillator | 3.18 | 21.86 |
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 81% from Macao, with the rest largely from the Philippines as of 2024.